Explorez tous les épisodes du podcast The Retina Channel Podcast
| Titre | Date | Durée | |
|---|---|---|---|
| E81- Laser Retinopexy in Eyes With High-Risk Lattice Degeneration- Dr. Marc Spirn | 07 Oct 2024 | 00:23:19 | |
Dr. Marc Spirn from Wills Eye Hospital discusses the results of a retrospective study of performing lattice degeneration on a series of patients who had lattice degeneration with high risk features.
The discussed article: Kazan AS, Mahmoudzadeh R, Salabati M, Sharpe J, Fineman MS, Hsu J, Yonekawa Y, Spirn MJ. Indications and Outcomes of Laser Retinopexy in Eyes With High-Risk Lattice Degeneration. J Vitreoretin Dis. 2024 Apr 25;8(4):381-387. doi: 10.1177/24741264241248253. PMID: 39148566; PMCID: PMC11323511. | |||
| E80-Retinal Vasculitis After Intravitreal Pegcetacoplan- Dr. Andre Witkin from ASRS Research and Safety in Therapeutics (ReST) Committee | 05 Aug 2024 | 00:27:16 | |
Dr. Witkin from the American Society of Retina Specialists talks about our current knowledge of the incidence of retinal vasculitis following intravitreal injection of Pegcetacoplan for treatment of geographic atrophy. Discussed article: Witkin AJ, Jaffe GJ, Srivastava SK, Davis JL, Kim JE. Retinal Vasculitis After Intravitreal Pegcetacoplan: Report From the ASRS Research and Safety in Therapeutics (ReST) Committee. J Vitreoretin Dis. 2023 Dec 21;8(1):9-20. doi: 10.1177/24741264231220224. Erratum in: J Vitreoretin Dis. 2024 Feb 29;8(3):363. doi: 10.1177/24741264241238212. PMID: 38223782; PMCID: PMC10786078. | |||
| E71- GA progression on Asian vs non-Asian Eyes- Prof Gemmy Cheung | 16 Sep 2023 | 00:18:11 | |
Prof. Gemmy Cheung from the National University of Singapore and Singapore National Eye Center discusses her research results on progression of Geographic Atrophy on Asian vs non-Asian Eyes. References Article: Teo KYC, Fujimoto S, Sadda SR, Kokame G, Gomi F, Kim JE, Cheng MFS, Corradetti G, Amornpetchsathaporn A, Chainakul M, Lee WK, Lai TYY, Ruamviboonsuk P, Cheung CMG. Geographic Atrophy Phenotypes in Subjects of Different Ethnicity: Asia-Pacific Ocular Imaging Society Work Group Report 3. Ophthalmol Retina. 2023 Jul;7(7):593-604. doi: 10.1016/j.oret.2022.12.013. Epub 2022 Dec 28. PMID: 36586466. | |||
| E70-Archway 3 Port Delivery System for wAMD- Dr. Carl Regillo | 26 Jul 2023 | 00:30:51 | |
Dr. Regillo describes the results of the phase 3 prospective study of Ranibizumab Port Delivery System (PDS) for the treatment of neovascular AMD. Reference Article: Regillo C, Berger B, Brooks L, Clark WL, Mittra R, Wykoff CC, Callaway NF, DeGraaf S, Ding HT, Fung AE, Gune S, Le Pogam S, Smith R, Willis JR, Barteselli G. Archway Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration 2-Year Results. Ophthalmology. 2023 Jul;130(7):735-747. doi: 10.1016/j.ophtha.2023.02.024. Epub 2023 Mar 2. PMID: 36870451. | |||
| E69- DRCR Protocol AC Cost Analysis- Dr. William Smiddy | 19 Jun 2023 | 00:33:06 | |
Dr. Smiddy presents a cost analysis of the step therapy for treatment of diabetic macular edema based on DRCR protocol AC results. Discussed article: Patel NA, Al-Khersan H, Yannuzzi NA, Lin J, Smiddy WE. Aflibercept Monotherapy versus Bevacizumab-First for Diabetic Macular Edema: A Cost Analysis Based on Diabetic Retinopathy Clinical Research Network Protocol AC Results. Ophthalmol Retina. 2023 May;7(5):413-419. doi: 10.1016/j.oret.2022.11.010. Epub 2022 Nov 22. PMID: 36423893. | |||
| E68-Retinectomy without Lensectomy for RD with PVR- Dr. Jason Hsu | 09 May 2023 | 00:22:56 | |
Dr. Jason Hsu from Wills Eye Hospital returns to The Retina Channel to discuss his groups' retrospective study of eyes with advanced retinal detachement (PVR grade C or worse) that underwent retinectomy without lensectomy. Their study showed that 75% of these eyes at 3 months (and 68% at 6 months) had single surgery anatomic success. The study is suggestive that lensectomy and even peripheral vitreous base sheving may not be necessary when doing retinectomy for advanced RD cases. Full reference to the article: Mahmoudzadeh R, Mokhashi N, Anderson H, Patel S, Salabati M, Chiang A, Kuriyan AE, Gupta OP, Mehta S, Garg SJ, Hsu J. Outcomes of Retinectomy without Lensectomy in Rhegmatogenous Retinal Detachments with Proliferative Vitreoretinopathy. Ophthalmol Retina. 2023 Jan;7(1):52-58. doi: 10.1016/j.oret.2022.07.008. Epub 2022 Aug 5. PMID: 35940476. | |||
| E67-DAVIO Trial- extended release EYP-1901 for wet AMD- Dr. Jay Duker | 10 Apr 2023 | 00:35:23 | |
Dr. Jay Duker speaks about the results of the DAVIO trial which was a phase 1 trial investigating an intravitreal implant (EYP-1901) containg vorolanib (a VEGF and receptor blocker) in a bioerodible Durasert implant for the treatment of wet AMD. | |||
| E66-DIAMONDS Study- Micropulse Laser vs Standard Laser for DME- Prof. Noemi Lois | 07 Mar 2023 | 00:43:05 | |
Dr. Noemi Lois from Queens University in Belfast, UK discusses results of the DIAMONDS study, which was a prospective trial that looked into the effectiveness, safety, and cost-effectiveness of subthreshold micropulse laser (SML), compared with standard laser (SL), for diabetic macular edema (DME) with central retinal thickness (CRT) < 400 um. Referenced article: Lois N, Campbell C, Waugh N, Azuara-Blanco A, Maredza M, Mistry H, McAuley D, Acharya N, Aslam TM, Bailey C, Chong V, Downey L, Eleftheriadis H, Fatum S, George S, Ghanchi F, Groppe M, Hamilton R, Menon G, Saad A, Sivaprasad S, Shiew M, Steel DH, Talks JS, Doherty P, McDowell C, Clarke M; DIAMONDS Study Group. Diabetic Macular Edema and Diode Subthreshold Micropulse Laser: A Randomized Double-Masked Noninferiority Clinical Trial. Ophthalmology. 2023 Jan;130(1):14-27. doi: 10.1016/j.ophtha.2022.08.012. Epub 2022 Aug 13. PMID: 35973593. | |||
| E65-Incidence of delayed retinal tears after symptomatic PVD- Dr. Jing Chen | 01 Dec 2022 | 00:20:21 | |
Dr. Xuejing Chen discusses her group's retrospective analysis of the incidence and risk factors of delayed retinal breaks following a symptomatic posterior vitreous detachment. Discussed article: Jindachomthong KK, Cabral H, Subramanian ML, Ness S, Siegel NH, Chhablani J, Hsu SX, Chen X. Incidence and risk factors for delayed retinal tears following an acute, symptomatic posterior vitreous detachment. Ophthalmol Retina. 2022 Oct 25:S2468-6530(22)00514-0. doi: 10.1016/j.oret.2022.10.012. Epub ahead of print. PMID: 36307014. | |||
| E64-DRCR Protocol AC-Aflibercept Monotherapy or Bevacizumab First for DME- Dr. Chirag Jhaveri | 30 Oct 2022 | 00:34:06 | |
Dr. Jhavery discusses results of DRCR Retina Protocol AC study which compared DME response to anti-VEGF injections in patients who received Aflibercept monotherapy vs those who started with Bevacizumab first and then switched to Aflibercept if needed. Discussed article: Jhaveri CD, Glassman AR, Ferris FL 3rd, Liu D, Maguire MG, Allen JB, Baker CW, Browning D, Cunningham MA, Friedman SM, Jampol LM, Marcus DM, Martin DF, Preston CM, Stockdale CR, Sun JK; DRCR Retina Network. Aflibercept Monotherapy or Bevacizumab First for Diabetic Macular Edema. N Engl J Med. 2022 Aug 25;387(8):692-703. doi: 10.1056/NEJMoa2204225. Epub 2022 Jul 14. PMID: 35833805. | |||
| E63- Vitrectomy vs Vitrectomy plus Scleral Buckle for Repair of Retina Detachments Due to Giant Retina Tears- Dr. Fernando Arevalo | 15 Sep 2022 | 00:25:29 | |
Dr. J. Fernando Arevalo discusses results of an international multicenter study that compared surgical success rates of vitrectomy vs vitrectomy + scleral buckle to repair retinal detachments due to giant retinal tears. The study collected 200 patients data over a 12 year period. Referenced article: Ong SS, Ahmed I, Gonzales A, Al-Fakhri AS, Al-Subaie HF, Al-Qhatani FS, Alsulaiman SM, Mura M, Maia M, Kondo Kuroiwa DA, Maia NT, Berrocal MH, Wu L, Zas M, Francos JP, Cubero-Parra JM, Arsiwala LT, Handa JT, Arevalo JF. Vitrectomy versus Vitrectomy with Scleral Buckling in the Treatment of Giant Retinal Tear Related Retinal Detachments: An International Multicenter Study. Ophthalmol Retina. 2022 Jul;6(7):595-606. doi: 10.1016/j.oret.2022.03.004. Epub 2022 Mar 15. PMID: 35304304. | |||
| E62-CRVO and HRVO Associated with COVID-19 Infection in Young Patients-Dr. Avni Finn | 27 Jun 2022 | 00:19:48 | |
Dr. Finn discusses her groups' case series on temporal associattion CRVO and HRVO in young healthy patients after COVID-19 infection. Discussed article: Ashkenazy N, Patel NA, Sridhar J, Yannuzzi NA, Belin PJ, Kaplan R, Kothari N, Benitez Bajandas GA, Kohly RP, Roizenblatt R, Pinhas A, Mundae R, Rosen RB, Ryan EH Jr, Chiang A, Chang LK, Khurana RN, Finn AP. Hemi- and Central Retinal Vein Occlusion Associated with COVID-19 Infection in Young Patients without Known Risk Factors. Ophthalmol Retina. 2022 Jun;6(6):520-530. doi: 10.1016/j.oret.2022.02.004. Epub 2022 Mar 10. PMID: 35278727; PMCID: PMC8907133. | |||
| E79- Interaction Between Optometry and The Specialty of Retina- Panel Discussion | 27 Jul 2024 | 00:28:57 | |
A panel of guests optometrists share their feedback about communication issues between optometry and the speciality of retina. Guests panelists: Dr. George Papadakis, Dr. Brian Feinstein, Dr. Lena Moiseiykina and Dr. Nagar Sohbati. | |||
| E61- Air vs SF6 for small-medium macular holes- Dr. Birger Lindtjørn | 23 May 2022 | 00:19:48 | |
Dr. Birger Lindtjørn from Norway discusses his team's prospective trial on comparison of SF6 vs air tamponade in vitrectomy for closure of small-medium macular holes. Discussed article: Lindtjørn B, Krohn J, Haugstad M, Stene-Johansen I, Austeng D, Basit S, Fossen K, Varhaug P, Kvaløy JT, Forsaa VA. Air versus Sulfur Hexafluoride Gas Tamponade for Small and Medium-Sized Macular Holes: A Randomized Noninferiority Trial. Ophthalmol Retina. 2022 Apr 7:S2468-6530(22)00179-8. doi: 10.1016/j.oret.2022.04.003. Epub ahead of print. PMID: 35398546. | |||
| E60-Reticular Pseudodrusen and Progression to Advanced AMD- Prof. Robyn Guymer | 02 May 2022 | 00:19:12 | |
Prof. Guymer from Melbourne Univeristy discusses finding of a prospective study on absence of association between retinal pseudodrusen and advanced AMD. Discussed article: Wu Z, Kumar H, Hodgson LAB, Guymer RH. Reticular Pseudodrusen on the Risk of Progression in Intermediate Age-Related Macular Degeneration. Am J Ophthalmol. 2022 Mar 11:S0002-9394(22)00101-5. doi: 10.1016/j.ajo.2022.03.007. Epub ahead of print. PMID: 35288077. | |||
| E59-Novel RCBTB1 variants and late-onset retinal dystrophy- Dr. Brian Ballios | 21 Mar 2022 | 00:36:59 | |
Dr. Ballios discusses his group's findings on novel mutations in the RCBTB1 gene that can cuase late-onset non-syndromic retinal dystrophies mimicking macular degeneration. Full article: Catomeris AJ, Ballios BG, Sangermano R, Wagner NE, Comander JI, Pierce EA, Place EM, Bujakowska KM, Huckfeldt RM. Novel RCBTB1 variants causing later-onset non-syndromic retinal dystrophy with macular chorioretinal atrophy. Ophthalmic Genet. 2022 Jan 20:1-8. doi: 10.1080/13816810.2021.2023196. Epub ahead of print. PMID: 35057699. | |||
| E58-Drainage Techniques for Retina Detachment Repair-Dr. Vinod Kumar | 28 Feb 2022 | 00:19:51 | |
Dr. Kumar discussed his group's prospective study on the comparative outcomes of two different drainage techniques (posterior retinotomy vs PFCL) for repair of rhegmatogenous retina detachment. | |||
| E57-PAMM and the Ischemic Cascade- Dr. David Sarraf | 17 Jan 2022 | 00:14:08 | |
Dr. David Sarraf from UCLA discusses Paracentral Acute Middle Maculopathy (PAMM) and its the ischemic implications. Discussed article: Wang D, Au A, Duker JS, Sarraf D. PAMM and the ischemic cascade associated with radiation retinopathy. Am J Ophthalmol Case Rep. 2020 Sep 8;20:100918. doi: 10.1016/j.ajoc.2020.100918. PMID: 32984654; PMCID: PMC7495006. | |||
| E56-C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy- Dr. Kourous Rezaei | 24 Dec 2021 | 00:30:18 | |
Dr. Kourous Rezaei reviews the results of the GATHER1 trial on complement C5 inhibition for slowing down progression of geography atrophy in dry AMD. References article: Jaffe GJ, Westby K, Csaky KG, Monés J, Pearlman JA, Patel SS, Joondeph BC, Randolph J, Masonson H, Rezaei KA. C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial. Ophthalmology. 2021 Apr;128(4):576-586. doi: 10.1016/j.ophtha.2020.08.027. Epub 2020 Sep 1. PMID: 32882310.
| |||
| E55-Minimized Eye Movement and Laser for RD Repair- Dr. Gregg Kokame | 16 Nov 2021 | 00:16:24 | |
Dr. Kokame from the University of Hawaii reports a novel method of repairing certain types of retinal detachment using minimized eye movement followed by laser retinopexy. Referenced article: Kokame GT, Yee S, Omizo JN, Villanueva L, Liu J. Laser Treatment after Minimized Eye Movement for Repair of Retinal Detachment. Ophthalmol Retina. 2021 Sep;5(9):939-941. doi: 10.1016/j.oret.2021.01.014. Epub 2021 Jan 30. PMID: 33529816. | |||
| E54-Macular Hydrodissection, Scleral Needling and Preop Gas- Dr. Efrem Mandelcorn | 02 Nov 2021 | 00:44:05 | |
Dr. Efrem Mandelcorn from the University of Toronto talks about 3 different surgical techniques that he's published in 3 different articles: 1. Macular hydodissection for challenging macular holes: Felfeli T, Mandelcorn ED. MACULAR HOLE HYDRODISSECTION: Surgical Technique for the Treatment of Persistent, Chronic, and Large Macular Holes. Retina. 2019 Apr;39(4):743-752. doi: 10.1097/IAE.0000000000002013. PMID: 29303907.2. Scleral needling for closure of sclerotomies: Felfeli T, Altomare F, Mandelcorn ED. SUTURELESS CLOSURE OF 23- AND 25-GAUGE LEAKING SCLEROTOMIES WITH THE SCLERAL NEEDLING TECHNIQUE. Retina. 2020 May;40(5):838-844. doi: 10.1097/IAE.0000000000002484. PMID: 30821730. Link to the Scleral Needling technique 3. Pre-operative gas for repair of retinal detachment: Felfeli T, Mandelcorn MS, Trussart R, Mandelcorn ED. Preoperative Gas for Pars Plana Vitrectomy: A Surgical Technique for Repair of Rhegmatogenous Retinal Detachments with Multiple, Large or Inferior Breaks. Retin Cases Brief Rep. 2021 Oct 1. doi: 10.1097/ICB.0000000000001197. Epub ahead of print. PMID: 34652305. AAO 1-minute video | |||
| E53-Optogenetic Vision Recovery for Retinitis Pigmentosa-Drs. Sahel and Roska | 05 Oct 2021 | 00:29:52 | |
Professors Sahel and Roska describe partial visual recovery of a patient with advanced RP using optogenetic technology. Discussed article: Sahel JA, Boulanger-Scemama E, Pagot C, Arleo A, Galluppi F, Martel JN, Esposti SD, Delaux A, de Saint Aubert JB, de Montleau C, Gutman E, Audo I, Duebel J, Picaud S, Dalkara D, Blouin L, Taiel M, Roska B. Partial recovery of visual function in a blind patient after optogenetic therapy. Nat Med. 2021 Jul;27(7):1223-1229. doi: 10.1038/s41591-021-01351-4. Epub 2021 May 24. PMID: 34031601. | |||
| E52-Complications of Acute PVD- Dr. Michael Seider | 20 Sep 2021 | 00:40:05 | |
Dr. Seider elaborates on his group's large retrospective study on rates and risk factors for complicated acute posterior vitreous detachment. Full reference to the discussed article: Seider MI, Conell C, Melles RB. Complications of Acute Posterior Vitreous Detachment. Ophthalmology. 2021 Jul 27:S0161-6420(21)00552-2. doi: 10.1016/j.ophtha.2021.07.020. Epub ahead of print. PMID: 34324945. | |||
| E78- Effect of Scleral Buckle on Outflow Facility, Intraocular Pressure, and Ocular Biomechanics- Dr. Arthur Sit | 17 Jun 2024 | 00:30:32 | |
Dr. Arthur sit describes his surprising research results on the effect of scleral buckle on ocular fluid dynamics. The discussed article: Lyons LJ, Kazemi A, Bakri SJ, Barkmeier AJ, Iezzi R, Olsen TW, Hodge DO, Sit AJ. The Effect of Scleral Buckle Surgery on Tonographic Outflow Facility, Positional Intraocular Pressure, and Ocular Biomechanics. Ophthalmol Glaucoma. 2024 Jan-Feb;7(1):1-7. doi: 10.1016/j.ogla.2023.07.007. Epub 2023 Jul 22. PMID: 37482122. | |||
| E51-COVID-19 and anti-septics, Ocular Tissue Detection, & Ontario Surgical Backlog-Dr. Tina Felfeli | 19 Jul 2021 | 00:43:27 | |
Dr. Tina Felfeli discusses 3 articles around COVID-19 and ophthalmology: (1) Effect of various concretions and exposure times of common ophthalmology anti-septics on COVID-19 infected cell lines. (2) Effect of the pandemic on the backlog of elective ophthalmic surgical cases in the province of Ontario, Canada (3) Detection of the COVID-19 virus in different ocular tissues of a patient that tested positive for COVID-19. Referenced articles:
| |||
| E50-Vision Recovery Velocity, Momentum and Acceleration-Dr. David Almeida | 14 Jun 2021 | 00:32:30 | |
Dr. Almeida presents a mathematical model based on Newtonian mechanics to discuss vision recovery of different anti-VEGF medications. The discussed article: Almeida DRP, Ruzicki J, Xu K, Chin EK. Vision Recovery Velocity, Momentum and Acceleration: Advanced Vitreoretinal Analytics as Measure of Treatment Efficacy for Neovascular Age-Related Macular Degeneration. Clin Ophthalmol. 2021 Jan 18;15:189-194. doi: 10.2147/OPTH.S288621. PMID: 33500611; PMCID: PMC7822233.
| |||
| E49-SCREENROP Study. Refining ROP Screening Guidelines- Dr. Kourosh Sabri | 28 May 2021 | 00:47:18 | |
Dr. Sabri discusses his group's analysis of various screening criteria to detect visually significant Retinopathy of Prematurity while minimizing unnecessary retinal exams. Discussed article: Sabri K, Shivananda S, Farrokhyar F, Selvitella A, Easterbrook B Kin B, Seidlitz W, Lee SK; Canadian Neonatal Network and the Canadian Association of Pediatric Ophthalmology and Strabismus. Refining evidence-based retinopathy of prematurity screening guidelines: The SCREENROP study. Paediatr Child Health. 2019 Aug 12;25(7):455-466. doi: 10.1093/pch/pxz085. PMID: 33173557; PMCID: PMC7606175. | |||
| E48-DRCR Protocol W 2-year Results: Prophylactic anti-VEGF for Mod-Severe NPDR | 20 Apr 2021 | 00:32:02 | |
Dr. Raj Maturi from the DRCR Retina Network discusses effect of early anti-VEGF injections in moderate-severe NPDR to prevent vision-threatening complications of diabetic retinopathy. This is the 2-year results of a 4-year study. Discussed article: Maturi RK, Glassman AR, Josic K, Antoszyk AN, Blodi BA, Jampol LM, Marcus DM, Martin DF, Melia M, Salehi-Had H, Stockdale CR, Punjabi OS, Sun JK; DRCR Retina Network. Effect of Intravitreous Anti-Vascular Endothelial Growth Factor vs Sham Treatment for Prevention of Vision-Threatening Complications of Diabetic Retinopathy: The Protocol W Randomized Clinical Trial. JAMA Ophthalmol. 2021 Mar 30:e210606. doi: 10.1001/jamaophthalmol.2021.0606. Epub ahead of print. PMID: 33784735; PMCID: PMC8010644. | |||
| E47-Nondamaging Retinal Laser for Mac Tel Type II- Dr. Daniel Lavinsky | 13 Mar 2021 | 00:42:08 | |
Dr. Daniel Lavinsky describes the results of a small randomized controlled clinical trial investigating functional and anatomical outcomes of using nondamaging retinal laser for the treatment of macular telangiectasia type II. The discussed article: Lavinsky D, Silva MOD, Chaves AE, Schneider WFM, Lavinsky F, Palanker D. FUNCTIONAL AND STRUCTURAL EFFECTS OF NONDAMAGING RETINAL LASER THERAPY FOR MACULAR TELANGIECTASIA TYPE 2: A Randomized Sham-Controlled Clinical Trial. Retina. 2021 Mar 1;41(3):487-494. doi: 10.1097/IAE.0000000000002882. PMID: 33370517. | |||
| E46- DRCR Protocol AB. Anti-VEGF vs PPV for PDR w Vit Heme-Dr. Andrew Antoszyk | 13 Feb 2021 | 00:22:27 | |
Dr. Antoszyk from the DRCR Retina Network discusses Protocol AB, which compared anti-VEGF injections vs immediate pars plana vitrectomy for the treatment of vitreous hemorrhage due to proliferative diabetic retinopathy. The discussed article: Antoszyk AN, Glassman AR, Beaulieu WT, Jampol LM, Jhaveri CD, Punjabi OS, Salehi-Had H, Wells JA 3rd, Maguire MG, Stockdale CR, Martin DF, Sun JK; DRCR Retina Network. Effect of Intravitreous Aflibercept vs Vitrectomy With Panretinal Photocoagulation on Visual Acuity in Patients With Vitreous Hemorrhage From Proliferative Diabetic Retinopathy: A Randomized Clinical Trial. JAMA. 2020 Dec 15;324(23):2383-2395. doi: 10.1001/jama.2020.23027. PMID: 33320223; PMCID: PMC7739132. | |||
| E45- Stress in Medicine- Book Club with Dr. Nina Ahuja | 27 Jan 2021 | 00:32:12 | |
Dr. Nina Ahuja (@docsleadership) discusses her newly published booked titled "Stress in Medicine, Lessons Learned Through my Years as a Surgeon, from Med School to Residency, and Beyond". In an intimate account of her journey through her medical career, Dr. Ahuja discusses some of hardships and difficulties that she has gone through with the goal of bringing more transparency to the medical education and breaking the culture of silence. The book is available through Amazon and Apple Books. | |||
| E44- Representation of Women in Vitreoretinal Meetings- Dr. Jay Sridhar | 24 Dec 2020 | 00:25:10 | |
Dr. Sridhar (host of the Straight from the Cutter's Mouth podcast) discusses his recent article on the trends of women's representation in VR meetings in the US between 2015 and 2019. The discusses article: Sridhar J, Kuriyan AE, Yonekawa Y, Berrocal A, Khan MA, Chan RVP, Haller JA. Representation of Women in Vitreoretinal Meeting Faculty Roles from 2015 through 2019. Am J Ophthalmol. 2021 Jan;221:131-136. doi: 10.1016/j.ajo.2020.09.001. Epub 2020 Sep 9. PMID: 32918901; PMCID: PMC7736466. | |||
| E43- Retinal Findings in Hospitalized COVID-19 Patients- Dr. Leonardo Pereira | 03 Dec 2020 | 00:16:46 | |
Dr. Pereira speaks about his group's report on retinal findings in patients with severe COVID-19 infections who were admitted in the ICU. Discussed article: Pereira LA, Soares LCM, Nascimento PA, et al. Br J Ophthalmol Epub ahead of print: [please include Day Month Year]. doi:10.1136/bjophthalmol- 2020-317576 | |||
| E42-Peripheral Exudative Hemorrhagic Chorioretinopathy- Dr. Federico Zicarelli | 02 Nov 2020 | 00:27:20 | |
Dr. Zicarelli discusses his group's 10-yr retrospective analysis on the prognostic factors associated with Peripheral exudative hemorrhagic chorioretinpathy. Discussed article: Zicarelli F, Preziosa C, Staurenghi G, Pellegrini M. Peripheral exudative haemorrhagic chorioretinopathy: a widefield imaging study. Br J Ophthalmol. 2020 Sep 3:bjophthalmol-2020-317083. doi: 10.1136/bjophthalmol-2020-317083. PMID: 32883656 | |||
| E77-Indivisual and Systemic Risk Factors for Diabetic Vitrectomy- Dr. Paul Micevych | 14 May 2024 | 00:20:29 | |
Dr. Paul Micevych from the UC San Francisco discusses his group's work on systemic and individual risk factors leading to complicated diabetic retinopathy requiring vitrectomy. Discussed article: Micevych PS, Taha AM, Poddar A, Stewart JM. Individual and Systems-Based Risk Factors for Diabetic Vitrectomy in an Urban Safety-Net Hospital. Ophthalmol Retina. 2023 Dec;7(12):1027-1034. doi: 10.1016/j.oret.2023.05.014. Epub 2023 May 24. PMID: 37236319. | |||
| E41- Treatment of Secondary Macular Holes with Topical Therapy- Dr. John Niffenegger | 05 Oct 2020 | 00:16:22 | |
Dr. Niffenegger discusses a case series of secondary macular hole treatment with topical therapy. Discussed article: Niffenegger JH, Fong DS, Wong KL, Modjtahedi BS. Treatment of Secondary Full-Thickness Macular Holes with Topical Therapy. Ophthalmol Retina. 2020 Jul;4(7):695-699. doi: 10.1016/j.oret.2020.01.014. Epub 2020 Jan 28. PMID: 32284268. | |||
| E40-Retinal Vasculitis and Intraocular Inflammation with Brolucizumab - Dr. Caroline Baumal | 07 Sep 2020 | 00:28:12 | |
Dr. Baumal discusses features and outcomes of eyes with retinal vasculitis and intraocular inflammation after intravitreal injection of brolucizumab for treatment of neovascular age-related macular degeneration. Discussed article: Baumal CR, Spaide RF, Vajzovic L, et al. Retinal Vasculitis and Intraocular Inflammation after Intravitreal Injection of Brolucizumab [published online ahead of print, 2020 Apr 25]. Ophthalmology. 2020;S0161-6420(20)30371-7. doi:10.1016/j.ophtha.2020.04.017 | |||
| E39- Slit Lamp Shields and Face Masks for COVID-19. Dr. Victor Koh | 22 Aug 2020 | 00:20:06 | |
Dr. Koh from Singapore National University Hospital discusses his team's simulation study on aerosol transmission through slit lamp shields and face masks. Discussed article: Chuan OS, Bin Razali MA, Shaffiee L, Xing YJ, Yin Fei TT, Chee LS, Koh V, Do slit lamp shields and face masks protect ophthalmologists amidst COVID-19?, Ophthalmology (2020), doi: https://doi.org/10.1016/j.ophtha.2020.06.031. | |||
| E38-Retinal Biomarkers of Alzheimer's Disease- Drs. Cecilia Lee and Rajendra Apte | 14 Jul 2020 | 00:32:02 | |
Drs. Lee and Apte discuss their recent paper on our current understanding of using retinal imaging biomarkers to evaluate Alzheimer's disease. Discussed article: Lee CS, Apte RS, Retinal Biomarkers of Alzheimer's Disease, American Journal of Ophthalmology (2020), doi: https://doi.org/10.1016/j.ajo.2020.04.040.
| |||
| E37- Retinal Detachment Rates after Intravitreal Anti-VEGF Injections- Dr. Omesh Gupta | 08 Jun 2020 | 00:27:08 | |
Dr. Gupta discusses findings of this large retrospective study on the risk and associations of rhegmatogenous retinal detachment after intravitreal anti-VEGF injections. Discussed article: Storey PP, Pancholy M, Wibbelsman TD, et al. Rhegmatogenous Retinal Detachment after Intravitreal Injection of Anti-Vascular Endothelial Growth Factor. Ophthalmology. 2019;126(10):1424‐1431. doi:10.1016/j.ophtha.2019.04.037
| |||
| E36- COVID-19 and Preparedness among Ophthalmologists- International Panel Discussion. Drs. Dan Ting, Olivia Li and Steven Yeh | 20 Apr 2020 | 00:56:59 | |
In a panel discussion with Dr. Koushan, Drs. Daniel Ting, Olivia Li and Steven Yeh discuss the preparedness of ophthalmologists in the COVID-19 crisis. The discussion is based on the most recent Ophthalmology editorial: Preparedness among Ophthalmologists: During and Beyond the COVID-19 Pandemic. Olivia Li, Ji-PengWong, Tien Y.Wong, Edmund Y.Mehta, JodLin, HaotianLin, XiaofengStrouthidis, Nicholas G.Park, Ki HoFung, Adrian T.McLeod, Stephen D.Busin, MassimoParke, David W.Holland, Gary N.Chodosh, JamesYeh, StevenTing, Daniel S.W. et al. | |||
| E35- COVID-19 Mortality and Public Mask Usage- Dr. Christopher Leffler | 06 Apr 2020 | 00:27:38 | |
Dr. Leffler discusses his team's analysis of the country-wide mortality from COVID-19 pandemic and its correlation with mask usage by the public. Full reference: Leffler CT, Ing E, McKeown CA, Pratt D, Grzybowski A. Final Country-wide Mortality from the Novel Coronavirus (COVID-19) Pandemic and Notes Regarding Mask Usage by the Public. April 4, 2020. Available from: researchgate.net.
| |||
| E34- Progression of glaucoma after anti-VEGF injections in susceptible eyes- Dr. Eugene Shildkrot | 29 Mar 2020 | 00:22:44 | |
Dr. Shildkrot discusses progression of glaucomatous changes in 28 eyes that were receiving anti-VEGF injections. Discussed article: Effects of Intravitreal Anti-VEGF Therapy on Glaucoma-like Progression in Susceptible Eyes, Du, Jeanette MD; Patrie, James T ; Prum, Bruce E.; Netland, Peter A.; Shildkrot, Yevgeniy (Eugene) MD, Journal of Glaucoma: December 2019 - Volume 28 - Issue 12 - p 1035-1040 doi: 10.1097/IJG.0000000000001382 | |||
| LEAVO Trial - Comparison of Anti-VEGF drugs for Macular Edema Secondary to CRVO- Dr. Philip Hykin. | 27 Feb 2020 | 00:25:32 | |
Dr. Philip Hykin discusses the LEAVO trial which was a large prospective trial comparing the efficacy of three main anti-VEGF intravitreal injections (bevacizumab, ranibizumab and aflibercept) for treating macular edema secondary to Central Retinal Vein Occlusion. The discussed article: Clinical Effectiveness of Intravitreal Therapy With Ranibizumab vs Aflibercept vs Bevacizumab for Macular Edema Secondary to Central Retinal Vein Occlusion: A Randomized Clinical Trial. Hykin P, Prevost AT, Vasconcelos JC, Murphy C, Kelly J, Ramu J, Hounsome B, Yang Y, Harding SP, Lotery A, Chakravarthy U, Sivaprasad S; LEAVO Study Group. JAMA Ophthalmol. 2019 Aug 29. doi:10.1001/jamaophthalmol.2019.3305. | |||
| E32-Change in Management after Vitreous Culture in Endophthalmitis after Intravitreal Injections-Dr. James Vander | 28 Jan 2020 | 00:21:55 | |
Dr. Vander from Wills Eye Hospital discusses the effect of vitreous tap on the management of 60 cases of endophthalmitis post intravitreal anti-VEGF injections. The discussed article: Changes in Management Based on Vitreous Culture in Endophthalmitis After Intravitreal Anti-vascular Endothelial Growth Factor Injection. Patel SN, Storey PP, Pancholy M, Obeid A, Wibbelsman TD, Levin H, Hsu J, Garg SJ, Dunn JP, Vander JF. Am J Ophthalmol. 2019 Nov;207:224-231. doi: 10.1016/j.ajo.2019.06.008. Epub 2019 Jun 13 | |||
| E76-EDI landscape in Canadian Ophthalmology Residency Programs | 31 Mar 2024 | 00:45:52 | |
Dr. Nina Ahuja and Dr. Nupura Bakshi elaborate on the concept of Equity, Diversity and Inclusion in medicine and discuss their recent publication about the EDI landscape in the Canadian ophthalmology post-secondary programs. The discussed article: Lee EY, Farrokhyar F, Bakshi N, Levin LA, Ahuja N. Equity, diversity, and inclusion landscape in Canadian postgraduate medical education for ophthalmology. Can J Ophthalmol. 2024 Feb;59(1):31-39. doi: 10.1016/j.jcjo.2022.08.015. Epub 2022 Sep 24. PMID: 36162441. | |||
| E31- FLUID Study - Dr. Robyn Guymer | 10 Dec 2019 | 00:17:10 | |
Dr. Guymer discusses the results of the FLUID study which investigated whether some residual sub retinal fluid can be tolerated in neovascular macular degeneration. Full reference: Tolerating Subretinal Fluid in Neovascular Age-Related Macular Degeneration Treated with Ranibizumab Using a Treat-and-Extend Regimen. Guymer, Robyn H.Chang, Andrew et al. Ophthalmology, Volume 126, Issue 5, 723 - 734 | |||
| E30-Clinical Predictors of Low-Risk Histopathology for Retinoblastoma- Dr. Sameh Soliman | 29 Oct 2019 | 00:28:38 | |
Dr. Soliman discusses his team's analysis of clinical predictors of low histopathology in eyes that were enucleated because of retinoblastoma. The goal of the study is to find clinical indicators in retinoblastoma that could be used to salvage eyes via eye-preserving treatment methods instead of enucleation. | |||
| E29-Anti-VEGF Levels in Breast Milk after Intravitreal Injections-Drs. Muni and Juncal | 14 Sep 2019 | 00:21:36 | |
Drs. Muni and Juncal discuss their case series on the level of anti-VEGF drugs and VEGF-A levels on lactating mothers who had received intravitreal anti-VEGF injections.
Reference for the article: Ranibizumab and Aflibercept Levels in Breast Milk after Intravitreal Injection; Verena R. Juncal,Quratulain Paracha,Motaz Bamakrid, https://doi.org/10.1016/j.ophtha.2019.08.022 | |||
| E28-Brolucizumab for wet AMD (HAWK and HARRIER)- Dr. Pravin Dugel | 02 Sep 2019 | 00:19:55 | |
Dr. Dugel discusses 1 and 2 year results of HAWK and HARRIER on Brolucizumab for neovascular AMD. Full reference: Dugel, P. U., Koh, A., Ogura, Y., Jaffe, G. J., Schmidt-Erfurth, U., Brown, D. M., . . . Investigators, H. S. (2019). HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology. doi:10.1016/j.ophtha.2019.04.017
| |||